-
Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial
Atmowihardjo, L. N., Schippers, J. R., Duijvelaar, E., Bartelink, I. H., Bet, P. M., Swart, N. E. L., van Rein, N., Purdy, K., Cavalla, D., McElroy, A., Fritchley, S., Vonk Noordegraaf, A., Endeman, H., van Velzen, P., Koopmans, M., Bogaard, H. J., Heunks, L., Juffermans, N., Schultz, M. J., Tuinman, P. R., & 2 others , 1 Dec 2023, In: Critical care (London, England). 27, 1, p. 226 226.Research output: Contribution to journal › Article › Academic › peer-review
-
Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19
Baalbaki, N., Duijvelaar, E., Said, M. M., Schippers, J., Bet, P. M., Twisk, J., Fritchley, S., Longo, C., Mahmoud, K., Maitland-van der Zee, A. H., Bogaard, H. J., Swart, E. L., Aman, J. & Bartelink, I. H., 1 May 2023, In: European journal of pharmaceutical sciences. 184, 106418.Research output: Contribution to journal › Article › Academic › peer-review
-
Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial
CounterCOVID Collaborative Group, 28 Dec 2022, In: Journal of Cardiovascular Pharmacology. 80, 6, p. 783-791 9 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications